Tissue Regenix Group Past Earnings Performance
Past criteria checks 0/6
Tissue Regenix Group has been growing earnings at an average annual rate of 28.7%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been growing at an average rate of 14.3% per year.
Key information
28.7%
Earnings growth rate
62.1%
EPS growth rate
Biotechs Industry Growth | 11.5% |
Revenue growth rate | 14.3% |
Return on equity | -5.6% |
Net Margin | -5.8% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Tissue Regenix Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 29 | -2 | 14 | 0 |
30 Sep 23 | 28 | -2 | 14 | 0 |
30 Jun 23 | 27 | -2 | 14 | 0 |
31 Mar 23 | 26 | -2 | 14 | 0 |
31 Dec 22 | 24 | -3 | 13 | 0 |
30 Sep 22 | 23 | -3 | 13 | 0 |
30 Jun 22 | 22 | -4 | 13 | 0 |
31 Mar 22 | 21 | -4 | 13 | 0 |
31 Dec 21 | 20 | -5 | 12 | 0 |
30 Sep 21 | 19 | -8 | 12 | 0 |
30 Jun 21 | 18 | -12 | 12 | 0 |
31 Mar 21 | 17 | -12 | 12 | 0 |
31 Dec 20 | 16 | -12 | 13 | 0 |
30 Sep 20 | 17 | -10 | 12 | 1 |
30 Jun 20 | 16 | -7 | 11 | 2 |
31 Mar 20 | 16 | -8 | 12 | 2 |
31 Dec 19 | 17 | -9 | 14 | 2 |
30 Sep 19 | 15 | -9 | 13 | 2 |
30 Jun 19 | 15 | -10 | 14 | 2 |
31 Mar 19 | 15 | -10 | 15 | 2 |
31 Dec 18 | 15 | -10 | 15 | 2 |
30 Sep 18 | 14 | -11 | 15 | 2 |
30 Jun 18 | 12 | -12 | 15 | 2 |
31 Mar 18 | 10 | -13 | 15 | 2 |
31 Dec 17 | 7 | -12 | 14 | 2 |
31 Dec 16 | 2 | -13 | 14 | 2 |
31 Jul 16 | 2 | -14 | 12 | 5 |
30 Apr 16 | 1 | -15 | 12 | 5 |
31 Jan 16 | 1 | -13 | 10 | 5 |
31 Oct 15 | 1 | -13 | 10 | 5 |
31 Jul 15 | 1 | -12 | 9 | 5 |
30 Apr 15 | 0 | -12 | 8 | 5 |
31 Jan 15 | 0 | -11 | 8 | 5 |
31 Oct 14 | 0 | -12 | 8 | 5 |
31 Jul 14 | 0 | -12 | 8 | 6 |
30 Apr 14 | 0 | -11 | 7 | 6 |
31 Jan 14 | 0 | -9 | 5 | 6 |
31 Oct 13 | 0 | -8 | 5 | 4 |
31 Jul 13 | 0 | -6 | 4 | 3 |
Quality Earnings: TRX is currently unprofitable.
Growing Profit Margin: TRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRX is unprofitable, but has reduced losses over the past 5 years at a rate of 28.7% per year.
Accelerating Growth: Unable to compare TRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: TRX has a negative Return on Equity (-5.64%), as it is currently unprofitable.